Pharmaceutical evaluation of new compounds with potential therapeutic application in central disorders

• Grant number: 18/23087-8
• Support Opportunities: Regular Research Grants
• Duration: May 01, 2019 - April 30, 2021
• Field of knowledge: Biological Sciences - Pharmacology - General Pharmacology
• Principal Investigator: Rosangela Gonçalves Peccinini
• Grantee: Rosangela Gonçalves Peccinini
• Host Institution: Faculdade de Ciências Farmacêuticas (FCFAR). Universidade Estadual Paulista (UNESP). Campus de Araraquara. Araraquara , SP, Brazil
• Associated researchers: Marcelo Tadeu Marin

Abstract

Pharmacotherapy has been extensively applied on a wide variety of diseases, is usually of lower cost and risk and is the most frequently used method in the clinic for the treatment and prevention of acute and chronic diseases. It is imperative that the development of therapeutic alternatives occurs continuously, since new pandemics present themselves in modern times. The life expectancy of the world's population has increased significantly in recent years, and this has largely been attributed to technological development linked to access to pharmaceuticals, which have increased survival and quality of life by suppressing potentially fatal diseases and deceleration of the processes of "physiological aging", giving greater autonomy to the individual at the extremes of age.The natural process of human aging is related to neuronal changes associated with the appearance of a series of disorders of the central nervous system that affect the cognitive processes - among them, memory, attention, reasoning, language and comprehension. Also, cognitive deficits may also be associated with some pathological conditions, among them dementia associated with Parkinson's Disease and Alzheimer's disease, schizophrenia, depression, head trauma, epilepsy among others. The treatment of cognitive deficits involves the application of nootropic drugs, which often present multiple therapeutic applications in central disorders, even as adjuvants, as in epilepsy. Considering the extensive therapeutic application of levetiracetam (LEV) as nootropic, researchers from the Milagre Research Group of the Chemistry Institute of UNESP Araraquara performed the chemoenzymatic synthesis of LEV and a series of analogues and these novel molecules with potential nootropic and anticonvulsant activity have not yet been evaluated pharmacological aspects. Furthermore, other compounds with nootropic potential, which act as H3 receptor antagonists, were obtained by the research group of the Federal University of São Paulo (UNIFESP) and, likewise, these new drug candidates have not yet been studied. The present proposal brings together projects of partnership with these researchers of the synthesis area with the objective of evaluating these new compounds with potential application on central disorders, with in vitro and in vivo approaches, and thus provide subsidies for the development of pharmaceutical products whose therapeutic application result in a favorable clinical outcome, contributing to increase the quality and life expectancy of the population. (AU)